Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Intraoperative Probe Helps Identify Tumor Malignancy In Real Time

This article was originally published in The Gray Sheet

Executive Summary

A novel handheld device that detects differences in electromagnetic properties between malignant and benign tissue may provide real-time intraoperative tumor analysis, new research suggests

You may also be interested in...



Dune Medical Plans Summer Submission For Breast Cancer Probe PMA

Dune Medical will submit a PMA application this summer for its MarginProbe intraoperative real-time margin detection system for breast cancer surgery, according to Bill Densel, the firm's U.S. president

Dune Medical Plans Summer Submission For Breast Cancer Probe PMA

Dune Medical will submit a PMA application this summer for its MarginProbe intraoperative real-time margin detection system for breast cancer surgery, according to Bill Densel, the firm's U.S. president

Research In Brief

BioMimetic bone graft: External fixation supported by BioMimetic Therapeutics' Augment injectable bone graft (formerly branded as GEM OS2) leads to faster bone formation in closed distal radius wrist fractures than external fixation alone, results from a 21-patient pilot study show. The Tennessee company announced Oct. 29 that CT scans by an independent, blinded radiologist showed that 40% of Augment patients in the study had at least 25% bone-fill across the fracture gap three weeks after the procedure, compared to zero control patients. The company notes that the patients in the Augment-treated group were, on average, more osteoporotic (lower bone density) than the control group. As of Oct. 28, the firm had enrolled 314 patients at 34 sites in its North American pivotal trial of Augment in foot and ankle fractures; it expects to complete enrollment of the planned 396-patient trial by early 2009 (1"The Gray Sheet" Aug. 18, 2008, p. 17)

Related Content

UsernamePublicRestriction

Register

MT025945

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel